The emergence of novel antibodies, CAR-T and CAR-NK therapies in AML

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

Allogeneic CAR-NK cell therapy in R/R AML/MDSПодробнее

CAR-T vs CAR-NK for myelomaПодробнее

The current status of CAR T and CAR NK cells in multiple myelomaПодробнее

Key challenges in immunotherapy for AMLПодробнее

An introduction to CAR-T and CAR-NK cell therapy developmentПодробнее

WEBINAR: CAR T Cell TherapyПодробнее

iwAL 2019: CAR-T & cellular therapies in AML and ALLПодробнее

Challenges in developing CAR-T therapy for AMLПодробнее

Acute lymphoblastic leukemia (ALL): Treatment options managing side effects and research advancesПодробнее

From CAR NK cell research to clinical NK cell engineering [WEBINAR]Подробнее

CAR T Cell Therapy in MDS/AMLПодробнее

Current concepts and future developments in T-cell-based immunotherapy of AMLПодробнее

Insights into NKG2D-targeting CAR-T cells in R/R AMLПодробнее

CAR T Cell Therapy Explained (Animation) | City of HopeПодробнее

The future of CAR-T therapyПодробнее

Professor Katy Rezvani - CAR-NK therapyПодробнее

Novel allo-CART therapies and their role in the treatment of hematological malignanciesПодробнее

CCTX-001: a novel CAR-T therapy for AMLПодробнее

CAR-NK clinical trialsПодробнее

NK-CAR immunotherapy: the next stepsПодробнее